Beyond Air Reports Slight Revenue Increase and Higher Net Loss for Quarter Ended June 30, 2026

Beyond Air, Inc. reported its financial results for the three months ended June 30, 2026, revealing a slight increase in revenue to $1.77 million compared to $1.76 million in the same period last year. The company’s cost of revenues decreased from $1.60 million to $1.54 million, resulting in a gross profit of $225,000, consistent with the previous year. However, the company experienced a net loss of $8.15 million, slightly higher than the $8.08 million loss reported in the prior year. This translates to a net loss per share of $11.00, compared to $30.67 in the same quarter of 2025, reflecting the impact of a one-for-twenty reverse stock split executed in July 2026.

In terms of operational changes, Beyond Air's research and development expenses decreased significantly to $1.96 million from $3.09 million year-over-year, attributed to reduced spending in various areas including salaries and clinical studies. Selling, general, and administrative expenses increased to $4.88 million from $4.69 million, primarily due to higher operational costs. The company’s total operating expenses for the quarter were $6.84 million, down from $7.77 million in the previous year, indicating a focus on cost management.

Beyond Air has made strategic advancements, particularly in its product offerings. The company continues to market its LungFit® PH device, which received FDA approval in June 2022 and CE mark approval in November 2024. The device is designed to treat persistent pulmonary hypertension in newborns and has been launched in the U.S. and over 27 other countries. The company is also preparing for the launch of its second-generation device, LungFit® PH II, which is expected to expand its market reach significantly.

As of June 30, 2026, Beyond Air reported total assets of $32.89 million, down from $35.39 million at the end of the previous fiscal period. The company’s cash and cash equivalents decreased to $5.51 million from $6.74 million, while marketable securities also saw a decline. The company’s liabilities increased to $30.05 million from $29.18 million, primarily due to rising long-term debt. Beyond Air indicated that it expects to incur net losses and significant cash outflows for at least the next year, necessitating additional funding to support its operations and product development.

Looking ahead, Beyond Air remains focused on the commercialization of its LungFit® products and the development of new therapies. The company anticipates that its ongoing efforts to secure financing will enable it to meet its operational obligations. However, management acknowledged that the success of its product launches and the ability to raise capital will be critical to its future growth and sustainability.